T0	Interventions 0 10	Daclizumab
T1	Interventions 110 128	placebo-controlled
T2	Interventions 148 158	Daclizumab
T3	Interventions 304 322	whether daclizumab
T4	Interventions 523 541	placebo-controlled
T5	Interventions 872 918	of daclizumab HYP 150 mg or 300 mg, or placebo
T6	Interventions 1323 1338	receive placebo
T7	Interventions 1344 1361	to daclizumab HYP
T8	Interventions 1378 1395	to daclizumab HYP
T9	Interventions 1546 1562	given daclizumab
T10	Interventions 1710 1721	those given
T11	Interventions 1776 1798	free in the daclizumab
T12	Interventions 1840 1847	than in
T13	Interventions 1944 1955	patients in
T14	Interventions 2125 2149	patient given daclizumab
T15	Interventions 2255 2293	INTERPRETATION Subcutaneous daclizumab
T16	Interventions 2453 2477	potential for daclizumab